They were competing across four categories including: product innovation, service innovation, digital innovation and innovative established business. There is also an overall winner and audience winner which will be chosen by attendees after the finalists make their pitches at the Manchester Central event on Thursday September 13. Each award comes with thousands of pounds worth of business support for the winner, provided by organisers GC Business Growth Hub and its partners. The competition is one of the highlights of the Venturefest North West 2018 programme, sponsored by NatWest, Dehns, Manchester Metropolitan University and Pomegranate Consulting. A full programme includes keynote speeches from Jenny Tooth CEO of the UK Business Angels Association and Richard Noble project director of the Bloodhound Super Sonic Car project, which will attempt to break the land speed record next year. Richard said: “Nothing about the Bloodhound project is easy and it never will be, but success here will bring great rewards in terms of education and confidence.

“I’m looking forward to sharing some of my learnings and experiences, as innovation is something that should apply to all businesses, large or small, in the north-west and across the country.” More than 1,000 attendees are expected at the event, where they will have access to business leaders and entrepreneurs, potential new partners, collaboration opportunities and a wide range of support. Heather Waters, national enterprise manager at headline sponsor NatWest, said: “We know that entrepreneurs and small business owners are looking for more than a provider of financial services. “They want a bank that helps them to concentrate on what’s important to them – establishing and growing their business. “That’s why we’re delighted to support Venturefest North West 2018 and be part of an event which gives businesses in the region the opportunity to innovate, grow and access the knowledge, finance and expertise they need to progress to the next stage of their business journey.”

The post Venturefest North West 2018: finalists revealed appeared first on CanCertain.

Founded in 2017 and led by Dr Himanshu Kataria, Director, Clyz is developing the Cancertain Assay as a service to select the best drug therapy for personalised cancer treatment. CLYZ Labs will combine information on drug sensitivity of the patient’s own tumor cells using innovative 3D Cell culture techniques along with biomarker and treatment guidelines to provide a personalised treatment recommendation. The company is advancing the first clinical trial involving its test, which has already secured all regulatory approvals.

The post Clyz Labs Raises Seed Funding appeared first on CanCertain.

Premier Corporate Finance supported CLYZ Labs in preparation for this fund-raising. CLYZ Labs, founded in 2017, are developing the Cancertain Assay as a service to select the best drug therapy for personalised cancer treatment. CLYZ Labs will combine information on drug sensitivity of the patient’s own tumor cells using innovative 3D Cell culture techniques along with biomarker and treatment guidelines to provide a personalised treatment recommendation. This is expected to increase life expectancy and reduce costs by selecting the best treatment option for an individual. CLYZ Labs has previously received funding from individual clinicians under SEIS and EIS Schemes, which supported pre-clinical development of the technology. The latest investment from GM&C Life Sciences Fund will enable the company to further optimise and validate the Cancertain Assay in patients with lung cancer and to generate much needed evidence in a clinical setting.

Dr Gareth King, Life Science Partner at Catapult Ventures, commented “Highly personalised cancer therapy is fast becoming the standard of care and I’ve been very impressed with the focus of CLYZ Labs team on improving outcomes for patients with cancer. CLYZ Labs is well positioned to provide a fully integrated service to support clinicians to provide the best treatment and care for patients. I look forward to the successful conclusion of this clinical trial.” Dr Himanshu Kataria, Director of CLYZ Labs, said “Lung cancer remains a major health problem with >65% patients dying within one year of diagnosis. We at CLYZ Labs are focused to ensure that every lung cancer patient gets the best chance at cancer treatment in the future. We welcome this initial investment from GM&C Life Sciences Fund, which will help us complete initial clinical validation of Cancertain Assay. Precision Medicine Tests require robust clinical and health economic evaluation before being made available to every patient under the NHS. We look forward to continue to work with the GM&C Life Sciences Fund and other investors to bring Cancertain Assay to every lung cancer patient in future.”

Mr Rupert Lewis, Partner at Premier Corporate Finance, said “We are delighted to be able to support Himanshu in his quest to improve cancer care within the current healthcare environment in the UK and international markets. I look forward to assisting with the future success of CLYZ Labs”.

The post Premier Corporate Finance advises CLYZ Labs on fund raising appeared first on CanCertain.

CLYZ Labs will combine information on drug sensitivity of the patient’s own tumor cells using innovative 3D Cell culture techniques along with biomarker and treatment guidelines to provide a personalised treatment recommendation. This is expected to increase life expectancy and reduce costs by selecting the best treatment option for an individual. CLYZ Labs has previously received funding from individual clinicians under SEIS and EIS Schemes, which supported pre-clinical development of the technology. The latest investment from GM&C Life Sciences Fund will enable the company to further optimise and validate the Cancertain Assay in patients with lung cancer and to generate much needed evidence in a clinical setting. Dr Gareth King, Life Science Partner at Catapult Ventures, commented “Highly personalised cancer therapy is fast becoming the standard of care and I’ve been very impressed with the focus of CLYZ Labs team on improving outcomes for patients with cancer.

CLYZ Labs is well positioned to provide a fully integrated service to support clinicians to provide the best treatment and care for patients. I look forward to the successful conclusion of this clinical trial.” Dr Himanshu Kataria, Director of CLYZ Labs, said “Lung cancer remains a major health problem with >65% patients dying within one year of diagnosis. We at CLYZ Labs are focused to ensure that every lung cancer patient gets the best chance at cancer treatment in the future. We welcome this initial investment from GM&C Life Sciences Fund, which will help us complete initial clinical validation of Cancertain Assay. Precision Medicine Tests require robust clinical and health economic evaluation before being made available to every patient under the NHS. We look forward to continue to work with the GM&C Life Sciences Fund and other investors to bring Cancertain Assay to every lung cancer patient in future.” Mr Rupert Lewis, Partner at Premier Corporate Finance, said “We are delighted to be able to support Himanshu in his quest to improve cancer care within the current healthcare environment in the UK and international markets. I look forward to assisting with the future success of CLYZ Labs”.

Photo, L-R: Dr Himanshu Kataria, Director, CLYZ Labs; Rupert Lewis, Partner, Premier Corporate Finance; Dr Gareth King, Life Science Partner, Catapult Ventures.

The post CLYZ Labs announces commencement of clinical trial and seed funding from Catapult Ventures to develop Cancertain™ test for personalised cancer treatment appeared first on CanCertain.

The post CLYZ Labs Ltd and Spheritech Ltd enter into an Agreement Of Collaboration appeared first on CanCertain.

CLYZ Labs is pleased to announce that it has received the HMRC Advanced Assurance for SEIS/EIS Scheme(s).

The Enterprise Investment Scheme (EIS) and Seed Enterprise Investment Scheme (SEIS) are government initiatives offering some of the most attractive tax breaks available in the UK. For the investor, it’s a tax efficient way to invest in small companies.

The EIS is aimed at the wealthier, sophisticated investors. People can invest up to £1,000,000 in any tax year and receive 30% tax relief. However, they are locked into the scheme for a minimum of three years. EIS seeks to encourage investment into unlisted companies.

“Being able to achieve the successful Advanced Assurance from HMRC in record time without having to answer additional queries, is a testament to the business planning work completed by the Founders and to the team at Sapphire Capital Partners LLP who assisted us in achieving this feat. Clyz Labs is committed to create a significant shareholder value; and having qualified for the government initiatives – The Enterprise Investment Scheme (EIS) and Seed Enterprise Investment Scheme (SEIS)- is an attractive incentive for investors to back the Clyz Mission to accelerate the development of new and existing therapies for the Cancer patients in UK and worldwide.” said Dr Himanshu Kataria – the founder & CEO of CLYZ labs.

Boyd Carson, Partner at Sapphire Capital Partners LLP added “Robust business plan and other preparatory work done by Clyz’s Directors helped us achieve this successful HMRC Advanced assurance within 5 weeks. We wish Clyz Labs every success in their mission to improve the health of cancer patients.”

Please do not hesitate to contact Zalak.Kataria@cancertain.com if you need any further information.

CLYZ Labs is an early stage biotechnology company based in United kingdom. Its mission is to collaboratively leverage existing cutting-edge technological innovations to improve the quality of life and survival of cancer patients by our work in clinical and pre-clinical stages of cancer therapies. Clyz Labs vision is to provide every cancer patient with our specialised diagnostic test to Personalised Therapy leading to improved quality of life and overall survival backed by reliable clinical trials. Clyz labs is committed to provide accurate, reliable, validated laboratory results to guide the Personalised Therapy for the Cancer patient.

Sapphire Capital Partners LLP is authorised and regulated by the Financial Conduct Authority. It specialises in tax efficient schemes (such as SEIS, EIS, VCT & SITR) to grow companies and investment funds. It assist clients in achieving SEIS, EIS and SITR HMRC advance assurance, raise funds and act as an FCA approved investment manager to SEIS, EIS & SITR funds as well as Alternative Investment Funds.

The post Early Stage Biotechnology Company CLYZ Labs receives HMRC Advanced Assurance for SEIS/EIS Scheme(s) appeared first on CanCertain.

The post CLYZ Labs Completes Round 1 Fund raising under SEIS appeared first on CanCertain.

The Enterprise Investment Scheme (EIS) and Seed Enterprise Investment Scheme (SEIS) are government initiatives offering some of the most attractive tax breaks available in the UK. For the investor, it’s a tax efficient way to invest in small companies.

The EIS is aimed at the wealthier, sophisticated investors. People can invest up to £1,000,000 in any tax year and receive 30% tax relief. However, they are locked into the scheme for a minimum of three years. EIS seeks to encourage investment into unlisted companies.

“Clyz Labs is committed to create a significant shareholder value; and being able to qualify for the government initiatives – The Enterprise Investment Scheme (EIS) and Seed Enterprise Investment Scheme (SEIS)- is an additional bonus for investors to back the Clyz Mission to accelerate the development of new and existing therapies for the Cancer patients in UK and worldwide. We welcome the expertise of Sapphire Capital Partners, and look forward to long-lasting business relationship.” said Dr Himanshu Kataria – the founder & CEO of CLYZ labs.

Boyd Carson, Partner at Sapphire Capital Partners LLP added “We are glad to be able to support the Clyz Labs in preparation of its HMRC Advance Assurance. We wish Clyz Labs every success in their mission to improve the health of cancer patients.”

Please do not hesitate to contact Zalak.Kataria@cancertain.com if you need any further information.

CLYZ Labs is an early stage biotechnology company based in United kingdom. Its mission is to collaboratively leverage existing cutting-edge technological innovations to improve the quality of life and survival of cancer patients by our work in clinical and pre-clinical stages of cancer therapies. Clyz Labs vision is to provide every cancer patient with our specialised diagnostic test to Personalised Therapy leading to improved quality of life and overall survival backed by reliable clinical trials. Clyz labs is committed to provide accurate, reliable, validated laboratory results to guide the Personalised Therapy for the Cancer patient.

Sapphire Capital Partners LLP is authorised and regulated by the Financial Conduct Authority. It specialises in tax efficient schemes (such as SEIS, EIS, VCT & SITR) to grow companies and investment funds. It assist clients in achieving SEIS, EIS and SITR HMRC advance assurance, raise funds and act as an FCA approved investment manager to SEIS, EIS & SITR funds as well as Alternative Investment Funds.

The post Early Stage Biotechnology Company CLYZ Labs appoints Sapphire Capital Partners as Capital Advisors appeared first on CanCertain.

The post Early Stage Biotechnology Company of the year 2017 appeared first on CanCertain.

“This is an amazing news and that hard work gone into establishment of relatively new business has been recognized by GHP. It would not have been possible to achieve such an award without the extremely committed scientific team at Clyz Labs” said DrHimanshuKataria, CEO & Co-Founder of Clyz Labs Limited Please do not hesitate to contact Akansha.Rana@cancertain.com if you need any further information. CLYZ Labs is an early stage biotechnology company based in United kingdom. Its mission is to collaboratively leverage existing cutting-edge technological innovations to improve the quality of life and survival of cancer patients by our work in clinical and pre-clinical stages of cancer therapies. Clyz Labs vision is to provide every cancer patient with our specialised diagnostic test to Personalised Therapy leading to improved quality of life and overall survival backed by reliable clinical trials. Clyz labs is committed to provide accurate, reliable, validated laboratory results to guide the Personalised Therapy for the Cancer patient. GHP is a global information sharing platform & a multi-disciplinary members community. GHP platform had over 185,700 page views in the last 12 months averaging at 15,400 page views per month. International Life Sciences Awards 2017 involved a rigorous research process which is a combination of an online voting form as well as GHP in-house research team.

The post CLYZ Labs awarded with Early-Stage Biotechnology Company of the Year 2017 at International Global Health & Pharma Awards. appeared first on CanCertain.